Neumann Mark 4
4 · Veradermics, Inc · Filed Feb 5, 2026
Research Summary
AI-generated summary of this filing
Veradermics (MANE) CCO Mark Neumann Receives Award
What Happened Mark Neumann, Chief Commercial Officer and Strategy Officer of Veradermics (MANE), was granted a derivative award of 102,885 shares (reported as an option grant) on February 3, 2026. The Form 4 records the acquisition under transaction code "A" (award/grant) and lists a price of $0.00 for the transaction. This is an equity compensation grant rather than an open-market purchase or sale.
Key Details
- Transaction date: 2026-02-03 (Form 4 filed 2026-02-05; appears timely).
- Award: 102,885 derivative shares (option grant), transaction code A.
- Price reported in filing: $0.00 (listed on Form 4).
- Shares owned after transaction: Not specified in the provided filing excerpt.
- Vesting (footnote): 25% of the underlying shares vest on Feb 3, 2027 (one-year cliff); remaining shares vest in equal monthly installments over the following 36 months, subject to continued service.
- Not an exercise or immediate sale—this is a grant of an equity award.
Context This filing reflects a standard executive equity grant used for compensation and retention. As a derivative option award, the grant vests over time per the schedule above; it does not represent an immediate open-market purchase or sale of shares. No additional indicators (such as a cashless exercise or sale) are shown in this filing.
Insider Transaction Report
- Award
Stock Option (Right to Buy)
[F1]2026-02-03+102,885→ 102,885 totalExercise: $17.00Exp: 2036-02-03→ Common Stock (102,885 underlying)
Footnotes (1)
- [F1]The option vests as to 25% of the underlying shares of the Issuer's common stock, par value $0.00001 per share, on February 3, 2027, the first anniversary of the vesting commencement date, and as to the remaining shares, in equal monthly installments over 36 months thereafter, subject to continued service.